

Hossein Borghaei Do

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3629821/publications.pdf>

Version: 2024-02-01

65
papers

21,070
citations

147726

31
h-index

149623

56
g-index

66
all docs

66
docs citations

66
times ranked

20468
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 52-59.	1.1	11
2	Phase 3, randomized, placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab in patients with unresected stage I or II non-small cell lung cancer (NSCLC): KEYNOTE-867. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8597-TPS8597.	0.8	3
3	Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. <i>Cancer</i> , 2022, 128, 3067-3079.	2.0	15
4	Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 162-168.	0.5	90
5	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , 2021, 22, 178-186.	1.1	6
6	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	0.8	329
7	To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 894-896.	0.5	0
8	Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. <i>Cancers</i> , 2021, 13, 3164.	1.7	35
9	Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2577-2584.	1.9	66
10	Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). <i>Cancer</i> , 2020, 126, 260-270.	2.0	202
11	Targeting KRAS-Mutant Non-small Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 4208-4218.	0.8	30
12	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 4867-4877.	2.0	69
13	Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 243-248.	0.6	0
14	The BiTE (bispecific T cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. <i>Cancer</i> , 2020, 126, 3192-3201.	2.0	116
15	Biomarker Testing in Lung Cancer—What Does It Mean?. <i>JAMA Network Open</i> , 2020, 3, e207171.	2.8	1
16	Combining Immunotherapy and Chemotherapy for Non-small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 199-206.	0.4	30
17	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , 2019, 36, 2638-2678.	1.3	145
18	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1395-1408.	5.1	247

#	ARTICLE	IF	CITATIONS
19	The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. <i>Translational Lung Cancer Research</i> , 2019, 8, 413-428.	1.3	95
20	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031.	13.9	1,866
21	Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.	1.1	42
22	Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100126.	0.7	24
23	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 124-129.	0.5	187
24	Phase 1 study of AMG 757, a half-life extended bispecific T cell engager (BiTE) antibody construct targeting DLL3, in patients with small cell lung cancer (SCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8577-TPS8577.	0.8	11
25	Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. <i>Lung Cancer</i> , 2018, 119, 112-119.	0.9	11
26	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	13.9	2,469
27	Identifying and managing the adverse effects of immune checkpoint blockade. <i>Journal of Thoracic Disease</i> , 2018, 10, S480-S489.	0.6	78
28	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. <i>Journal of Oncology Practice</i> , 2018, 14, 529-535.	2.5	41
29	Immunotherapy of lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S395-S396.	0.6	1
30	Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with $\geq 1\%$ tumor PD-L1 expression: Results from CheckMate 227. <i>Journal of Clinical Oncology</i> , 2018, 36, 9001-9001.	0.8	79
31	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. <i>Oncologist</i> , 2017, 22, 700-708.	1.9	11
32	Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α -targeting antibody-drug conjugate, in patients with solid tumors. <i>Cancer</i> , 2017, 123, 3080-3087.	2.0	94
33	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , 2017, 18, 31-41.	5.1	845
34	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 640-650.e2.	1.1	5
35	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	13.9	2,145
36	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 33.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 83-88.	0.2	14
38	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. <i>Oncologist</i> , 2017, 22, 1232-1237.	1.9	109
39	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0784314 rgt /Over	0.784314	108
40	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	0.8	397
41	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	0.8	444
42	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , The, 2016, 17, 1497-1508.	5.1	1,279
43	Musashi-2 (MSI2) supports TGF- β 2 signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6955-6960.	3.3	120
44	Non-Small Cell Lung Cancer, Version 6.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 515-524.	2.3	323
45	Bilateral granulosa cell tumors: a novel malignant manifestation of multiple endocrine neoplasia 1 syndrome found in a patient with a rare <i>menin</i> in-frame deletion. <i>The Application of Clinical Genetics</i> , 2015, 8, 69.	1.4	5
46	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973
47	Overcoming the KRAS resistance mechanism by augmenting antibody-dependent cellular cytotoxicity. <i>Colorectal Cancer</i> , 2012, 1, 273-275.	0.8	0
48	Phase I Trial of Combination Therapy with 90y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin's Lymphoma, Final Report.. <i>Blood</i> , 2012, 120, 2753-2753.	0.6	0
49	Assessing CD137 (4-1BB) As a Therapeutic Target in B-Cell Neoplasms,. <i>Blood</i> , 2011, 118, 3735-3735.	0.6	0
50	Naptumomab estafenatox: a new immunoconjugate. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 273-279.	1.4	13
51	Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. <i>Future Oncology</i> , 2009, 5, 19-22.	1.1	2
52	Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4116-4123.	0.8	56
53	Immunotherapy of cancer. <i>European Journal of Pharmacology</i> , 2009, 625, 41-54.	1.7	85
54	Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2009, 2, 251.	1.0	1

#	ARTICLE	IF	CITATIONS
55	Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC): Results of OPN-017. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1286-1292.	0.5	47
56	CD4 Cell Count of More Than 250/Microl in the Peripheral Blood Is Associated with Improved Overall Survival in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Independent of the aalPI. <i>Blood</i> , 2008, 112, 3775-3775.	0.6	0
57	Peripheral Blood CD3+CD4+ and CD3 ⁺ CD56+ Cell Counts and Circulating Lymphoma Cells Are Significant Predictors of Overall Survival in Newly Diagnosed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2607-2607.	0.6	1
58	Phase I Trial of Combination Therapy with 90Y Ibritumomab Tiuxetan (Zevalin) and Gemcitabine in Patients with Non-Hodgkin TM s Lymphoma.. <i>Blood</i> , 2007, 110, 4485-4485.	0.6	0
59	Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. <i>Human Antibodies</i> , 2006, 15, 103-111.	0.6	13
60	CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb) - Preliminary Results of Subjects with Castleman TM s Disease from a Phase 1 Study in Selected Hematological Malignancies.. <i>Blood</i> , 2006, 108, 2728-2728.	0.6	1
61	Phase I Trial of Combination Therapy with 90Y Ibritumomab Tiuxetan and Gemcitabine in Patients with Non-Hodgkin TM s Lymphoma.. <i>Blood</i> , 2006, 108, 4710-4710.	0.6	0
62	Rituximab-Mediated ADCC Is Augmented by Concomitant Interference with Inhibitory Self-Recognition by Human NK Cells.. <i>Blood</i> , 2005, 106, 2456-2456.	0.6	1
63	Vinblastine, Mitoxantrone and Prednisone (MVP) Followed by Involved Field Radiotherapy (IF-XRT) for Early Clinical Stage Hodgkins TM s Lymphoma: Long Term Follow-Up.. <i>Blood</i> , 2005, 106, 2677-2677.	0.6	0
64	Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma. <i>Cancer</i> , 2004, 101, 2034-2041.	2.0	6
65	Safety and efficacy of radioimmunotherapy with Yttrium 90 ibritumomab tiuxetan (Zevalin). <i>Seminars in Nuclear Medicine</i> , 2004, 34, 4-9.	2.5	42